Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Gupta, 2020, Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-Cell lymphoma, Am J Kidney Dis, 76, 63, 10.1053/j.ajkd.2019.10.011

Gutgarts, 2020, Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery, Biol Blood Marrow Transplant, 26, 1071, 10.1016/j.bbmt.2020.02.012

Pasquini, 2019, Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US), Blood, 134, 764, 10.1182/blood-2019-124750

Jaglowski, 2019, Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry, Blood, 134, 766, 10.1182/blood-2019-130983

Ying, 2019, Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s lymphoma, Mol Ther Oncolytics, 15, 60, 10.1016/j.omto.2019.08.002

Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021

Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant, 25, 625, 10.1016/j.bbmt.2018.12.758

Perazella, 2018, Nephrotoxicity of cancer immunotherapies: past, present, and future, J Am Soc Nephrol, 29, 2039, 10.1681/ASN.2018050488

Thaunat, 2006, Nephrotic syndrome associated with hemophagocytic syndrome, Kidney Int, 69, 1892, 10.1038/sj.ki.5000352